ABOUT

6th Gene Therapy Analytical Development & CMC Summit

Covering the full range of analytical methods across bioassays, molecular biology, and physicochemical properties, process-development and CMC, our comprehensive 3-track agenda will provide the technical detail and knowledge you need:

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Understand how to transition your potency assay from early to late-stage

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Explore how NGS methods can better inform your genome titers

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Accurately measure partials in your samples

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Produce contaminant-free and high yield vector batches at scale

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Leverage automation and in-process analytical tools to improve CMC efficiency on a platform level

Companies from biotech, pharma, and key service providers will be sharing data-driven and case-study led technical presentations on new technology and modifications to existing analytical processes for AAV-based gene therapies, as well as designing analytics for novel gene therapy capsids beyond traditional AAV and gene transfer to provide comprehensive, in-depth, and up-to-date information on the state of play in 2024.

VIEW EVENT GUIDE

What’s New for 2024?

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Leverage Brand-New Data & Case Studies to Better Characterize Your Gene Therapy Products

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Optimize your Full CMC Package Strategy to Meet Regulatory Requirements

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Unparalleled Networking Opportunities with Analytical & CMC Experts in Gene Therapy

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Understand how the Latest Analytical Innovations can be Applied in Practice

https://genetherapy-analytical.com/wp-content/uploads/sites/142/2019/07/cropped-GTx-AD-FAV-icon.png

Improve Upstream & Downstream Process Development to Ensure Product Quality & Reduce Cost of Goods

Who Will You Meet?

Join teams across analytical development, assay development, analytical chemistry and process development from the leading biotech and pharma companies in the space sharing technical and data-driven content on analytics for gene therapies across molecular biology, bioassays, physicochemical properties and CMC to cover the breadth and depth of analytical methods.

Graph 1 (1)
Graph 2 (1)

What Your Peers Have to Say:

"I attended last year the 5th Gene Therapy Analytical Development Summit. There were many topic is very interesting and informative. It was also a great opportunity to meet industry peers in person”

Haiqing Yu, Senior Scientist, Sanofi

“Having attended in the past, I am looking forward to seeing how the industry has progressed in the last year as it relates to analytical development. Innovation has become commonplace with AAV analytics and keeping up to date in latest trends and ideas is critical to remaining competitive”

John Reeves, PD Engineer, Regeneron

“The Gene Therapy Analytical Development Summit brings together scientists from many disciplines and provides a terrific overview of Gene Therapy analytics.”

Susan Rutberg, Director, Sanofi

“Looking forward to enlighten others about the underutilized of high rotor speeds to improve SV-AUC analysis that is particularly unique to large supramolecular structures (which represent the next generation of biopharmaceuticals) such as viral vectors (e.g. AAV)”

Steve Berkowitz, Independent Consultant, ex Biogen

“By presenting new data with emerging technology (CD-MS) from my side, extracting issues (especially when and how we can perform partial characterization) in biotech industry and suggesting possible solution to the companies will accelerate gene therapy development from analytical aspect, which is quite happy for me.”

Susumu Uchiyama, Professor, Osaka Univeristy

“This conference will contribute to your personal growth and continuous learning. Also, this conference is great way to meet new social and professional contacts”

Kashyap Pandya, Associate Director, PTC Therapeutics

“Great conference, on point agenda, valuable discussions”

Cecilia Della Valle, Director, PTC Therapeutics

EVENT GUIDE
REGISTER
PARTNER